EGFR Inhibitor-Associated Eruption
An epidermal growth factor receptor (EGFR) inhibitor-associated eruption is the most typical and most common member of the acneiform eruption family. It is an unwanted side effect of targeted cancer therapy, appearing in patients treated with tyrosine kinase inhibitors (such as erlotinib, gefitinib, afatinib and osimertinib) or with anti-EGFR monoclonal antibodies (such as cetuximab and panitumumab).
The way this rash develops has nothing in common with ordinary acne, which is driven by androgen imbalance, excess sebum and overgrowth of Cutibacterium acnes. EGFR is densely expressed on keratinocytes in the epidermis and the follicular epithelium. When a drug blocks EGFR signaling, keratinocytes no longer differentiate and mature normally. The skin barrier weakens, hair follicles degenerate and acute inflammatory cytokines are released. The result is a heavy inflammatory infiltrate, mostly neutrophils, around the follicular opening, which shows up as red papules and pustules.
At Haute-Derma, we assess the full pattern of skin lesions, grade severity against established medical criteria and review each patient's treatment history in detail. This lets us build a skin-support plan that fits the patient without interrupting their cancer treatment.
Clinical Features and Differential Diagnosis
On examination, a few characteristic features help separate an EGFR inhibitor rash from ordinary acne (acne vulgaris):
- Timing of onset: Lesions usually erupt early, within the first 1–2 weeks of starting EGFR-targeted therapy.
- Uniform lesions (monomorphism): The rash consists of inflamed red papules and pustules of similar size that appear all at once across the affected areas.
- No comedones: As with other acneiform eruptions, there are no whiteheads or blackheads. This is the key sign that rules out ordinary acne.
- Distribution: The rash concentrates in sebaceous-rich areas: the face (especially the T-zone), scalp, neck, upper chest and upper back.
- Associated symptoms: Unlike ordinary acne, the rash is often mildly to moderately itchy, with stinging, burning or widespread dryness.
Clinical Grading of EGFR Inhibitor Rash
| Grade | Clinical Features and Impact |
|---|---|
| Mild (Grade 1) | Papules and pustules confined to less than 10% of body surface area (BSA). Itch is mild or absent, and daily activities are unaffected. |
| Moderate (Grade 2) | Papules and pustules cover 10–30% of BSA, with noticeable itching and burning that partly limit daily self-care. |
| Severe (Grades 3–4) | Papules and pustules cover more than 30% of BSA, may become secondarily infected with bacteria, and cause severe pain and burning that seriously affect quality of life. |
The Haute-Derma Approach to Treatment
At Haute-Derma, our approach to acneiform eruptions rests on rigorous diagnostic criteria and a treatment plan tailored to each patient:
- Accurate diagnosis and clinical classification: The visit begins with a full assessment of the lesions, including a check for comedones, to tell an acneiform eruption apart from ordinary acne. The doctor also takes a detailed medication history (for example corticosteroids, EGFR inhibitors or antiepileptics) and asks about environmental and occupational exposures. If a microbial cause is suspected, direct microscopy or targeted microbiology tests are performed to look for overgrowth of Malassezia yeast, Demodex mites or Gram-negative bacteria.
- Managing the trigger: The first principle is to remove or control the cause. When the rash comes from a drug the patient needs for a serious underlying condition (such as EGFR-targeted cancer therapy or systemic corticosteroids), our dermatologists work closely with the treating specialist to adjust the dose or set up a supportive regimen without interrupting the main course of treatment.
- Cause-specific treatment: Once the cause is identified, the most appropriate medical therapy is chosen:
- Drug-induced inflammation (such as EGFR inhibition): oral antibiotics with anti-inflammatory activity (such as doxycycline), combined with suitable topical anti-inflammatory agents.
- Microbial forms: topical or oral antifungals targeting Malassezia, antiparasitic treatment for Demodex, or an appropriate antibiotic regimen for Gram-negative folliculitis.
- Restoring and protecting the skin barrier: Alongside medical treatment, patients learn a sensible skin-care routine that eases itching and burning and strengthens the barrier: gentle soap-free cleansers, fragrance-free moisturizers to restore normal hydration and diligent sun protection. Patients should never squeeze pustules or apply harsh exfoliating acne products on their own.
